EUROPE’S LEADING CONFERENCE ON

PSYCHEDELIC SCIENCE AND THERAPY

22 - 24 SEPTEMBER / HAARLEM

THURSDAY 22 SEPTEMBER

8:00 - 9:00 REGISTRATION 8:00 - 9:00

JOOST BREEKSEMA
9:15 - 9:40 9:15 - 9:40
ICPR 2022 official opening

DAVID NICHOLS
9:40 - 10:20 9:40 - 10:20
Overview of psychedelics, from prehistory to the present

10:20 - 10:30 ROOM CHANGE 10:20 -- 10:30

10:20 10:30

HUXLEY HALL SHULGIN

MUSIC STAGE
HALL WASSON ROOM

(Lack of) diversity and inclusion

(5-MeO-)DMT for depression Philosophy & phenomenology
in psychedelic research I

MICHELLE BAKER JONES JUUSO KÄHÖNEN

& GRAHAM CAMPBELL
10:30 - 10:55
Exploring the efficacy of DMT assisted
therapy as a treatment for depression
ERIKA DYCK
Psychedelic unselfing and change of values:
Psychedelic margins: reframing history for 10:30 - 10:45
can self-transcendence in psychedelic
a more inclusive psychedelic future experiences clarify values?

MICHAEL KRAMER
Toward a phenomenological philosophy 10:45 - 11:00
JOHANNES RECKWEG of psychedelics
HEVAL ÖZGEN
A phase 1/2 trial of GH001, a vaporized
Diversity, inclusion and equity in
10:55 - 11:20 5-methoxy-N,N-dimethyltryptamine
psychedelics science for marginalized GEORGE FEJER
formulation, in patients with treatment
populations A quantitative and qualitative phenomenology
resistant depression of serotonergic and anticholinergic 11:00 - 11:15
hallucinogens: evidence for multiple pathways
to hallucinatory consciousness

11:20 - 11:50 BREAK 11:20 - 11:50

Economics and commercialization

Psilocybin for depression Microdosing I
of psychedelics

DAVID ERRITZOE ELLIOT MARSEILLE KIM KUYPERS

11:50 - 12:10 Psilocybin vs escitalopram; 6 months Agenda for the economic evaluation of Microdosing psychedelics: where are 11:50 - 12:10
follow-up data and effects of expectation psychedelic therapies we and where to go from here?

MATTHEW WALL LIONEL THELEN

VINCE POLITO
Reduced brain responsiveness to emotional Psychedelics at the frontiers of science
12:10 - 12:30 Is microdosing just placebo? 12:10 - 12:30
stimuli with escitalopram but not psilocybin and… Beyond with the ERC funding
Reasons for and against
therapy for depression opportunities

METTEN SOMERS MICHAEL MULLETTE BALAZS SZIGETI

12:30 - 12:50 Single-dose psilocybin for a treatment MDMA-assisted therapy – the road to How to adjust microdosing trial results 12:30 - 12:50
resistant episode of major depression patient access for the quality of blinding?

12:50 - 14:20 LUNCH & POSTER PRESENTATIONS 12:50 - 14:20

Understanding MDMA-assisted
Mapping the psychedelic brain Psychedelics beyond the individual
therapy

MATTHEW BAGGOTT KATE GODFREY

YOGI HENDLIN
14:20 - 14:40 What are the neuropharmacological Electrophysiological (EEG) markers of human 14:20 - 14:40
Deep ecology and ecodelic experience
mechanisms of MDMA's magic? neuroplasticity in psychedelic research

PARKER SINGLETON DRUMMOND MCCULLOCH MATEO SANCHEZ PETREMENT

MDMA-assisted therapy alters neural
14:40 - 15:00
activity patterns in adults with chronic and
severe post-traumatic stress disorder
12:20 - 12:50
Psychedelic resting-state neuroimaging: a Resonance: situating experience and bridging
14:40 - 15:00
review and perspective on balancing the individual and social potentials of
replication and novel analyses psychedelics
 THURSDAY 22 SEPTEMBER

15:00 - 15:10 ROOM CHANGE 15:00 - 15:10

Therapeutic uses of
Mushrooms versus synthetic psilocybin Mysticism
psilocybin / mushrooms

(ONLINE) DANA SAWYER

PAUL STAMETS
Synthetic psilocybin vs.
15:10 - 15:50
psilocybin mushrooms:
neurogenerative properties
Aldous Huxley’s ‘minimum working
hypothesis’ of psychedelically occasioned
mystical experience(s) and why it continues
to be relevant for psychedelic studies today
AIDAN LYON
Can science and mysticism be reconciled?
WINSTON DE LA HAYE
Psychedelics for use and wellbeing; cultural
15:10 - 15:30
context and recent developments: a Jamaican
perspective
EMMANUELLE SCHINDLER
Efficacy and safety of psilocybin in the
prevention of headache disorders: results 15:30 - 15:50
from two preliminary clinical trials

15:50 - 16:20 BREAK 15:50 - 16:20

SYMPOSIUM
SYMPOSIUM SYMPOSIUM
Psychedelic research in the Netherlands
Access, reciprocity and conduct Psychedelic aesthetics
towards a network of excellence

MARCO AQIL
ANNE KATRIN SCHLAG Visual hallucinations: at the edge of
How can we ensure reciprocity and nature and culture
sustainability? Panelists
AMIR VUDKA JAN RAMAEKERS
JULIA BORNEMANN Drinking the cosmic soup: transcendental TIJMEN BOSTOEN
Access, equity, and harm reduction in the future style as a plane of immanence in the work
of Vincent Moon
MICHIEL VAN ELK
of psychedelic care
16:20 - 17:20 ROBERT SCHOEVERS 16:20 - 17:20
ASHLEIGH MURPHY-BEINER PATRICIA PISTERS BRIGITTE ADRIAENSEN
& ROBERTA MURPHY The limits of perception: nonhuman

Building a lighthouse: ethical guidelines for aesthetics and affective intensity Moderator
psychedelic therapists in clinical contexts
JOOST BREEKSEMA
SANDER BOS

KIRRAN AHMAD
Psychedelic art in a time of digital
Ibogaine and reciprocity
transformation

17:20 - 17:30 ROOM CHANGE 17:20 - 17:30

PANEL PANEL
Benefits, risks and challenges of ART PERFORMANCE Novel compounds or existing
therapist's self-experience molecules

Panelists Panelists
15:10 - 15:50 IVAR GOKSØYR DAVID NICHOLS
JANIS PHELPS MICHELLE BAKER-JONES

TORSTEN PASSIE PAUL STAMETS

17:30 - 18:15 Petites Planètes - Live Cinema by 17:30 - 18:15
ROBERTA MURPHY JUDY ASHWORTH
VINCENT MOON

Moderator Moderator
TIJMEN BOSTOEN MATTHEW BAGGOTT

18:15 - 19:15 RELAX & CONNECT 18:15 - 19:15

 FRIDAY 23 SEPTEMBER 10:20 - 10:30

9:00 - 9:30 ARRIVAL 9:00 - 9:30

HUXLEY HALL SHULGIN STAGE WASSON ROOM

Psychedelic therapy: Lessons from the (Lack of) diversity and inclusion
Dosing DMT
past and challenges for the future in psychedelic research II

TORSTEN PASSIE MONNICA WILLIAMS EMMA ECKERNÄS

Lessons from the first wave of psychedelic
9:30 - 9:55
research and therapy 1960-1975
The inclusion and exploitation of people of Understanding the relationship between DMT
exposure and its effects – implications for dose
9:30 - 9:55
color in psychedelic research
considerations

SONYA FABER LISA LUAN

CHARLES RAISON
The importance of cultural competency and
9:55 - 10:20 Five questions that will determine the future Using continuous infusion to extend the 9:55 - 10:20
anti-racist education for psychedelic assisted
of psychedelics in mainstream medicine DMT experience
therapy - understanding aversive racism

10:20 - 10:30 ROOM CHANGE 10:20 - 10:30

Palliative care Neuroscience of psychedelics Beyond mescaline

BILL RICHARDS DAVID NUTT CHRISTIAN POULIE

10:30 - 10:55 Psilocybin in palliative care: current The neuroscience of psychedelics in health Pharmacological evaluation of the ‘other’ 10:30 - 10:55
status and mental illness Lophophora alkaloids

HOUMAN FARZIN AMANDA FEILDING DINO LUETHI

LSD and the importance of changes in the
10:55 - 11:20 Psychedelic medicines for existential distress Beyond peyote: the pharmacology of 10:55 - 11:20
cerebral blood supply: from expanded states of
associated with life-threatening illnesses consciousness to new therapeutic interventions novel psychedelic phenethylamines

11:20 - 11:50 BREAK 11:20 - 11:50

Novel results from RCTs on

Psychedelic pharmacology Cognition and perception
anxiety and alcohol use disorders

PETER GASSER & FRIEDERIKE HOLZE ISABEL WIESSNER

LSD treatment in persons suffering from LSD and the stream of thought: increased
anxiety symptoms in severe somatic diseases MATTHIAS LIECHTI 11:50 - 12:10
discontinuity of mind, deep thoughts and
11:50 - 12:20
or in psychiatric anxiety disorders: a Dosing psychedelics abstract flow
randomized, double-blind, placebo-controlled
phase II study. History, Results, Outlook STEPHANIE MULLER
Effects of psilocybin on complex naturalistic 12:10 - 12:30
perception and expression
MICHAEL BOGENSCHUTZ ANNA BECKER
Effects of psilocybin in the treatment of Effects of the 5-HT2A receptor antagonist
12:20 - 12:50 NATASHA MASON
alcohol use disorder ketanserin after LSD administration in
Spontaneous and deliberate creative cognition 12:30 - 12:50
healthy subjects
during and after psilocybin exposure

12:50 - 14:20 LUNCH & POSTER PRESENTATIONS 12:50 - 14:20

14:00 - 14:10 INTROSPECTIVE MUSIC JOURNEY 14:00- 14:10

Challenging dominant
Therapeutic models Reciprocity
discourses on psychedelics

JEFF GUSS, JORDAN SLOSHOWER, VINCENT VERROUST

DAVID YADEN
ROB KRAUSE Psilocybin intellectual property, roots of
14:20 - 14:40 Addressing psilocybin research hype: an 14:20 - 14:40
Psychedelic phenomenology, the ACT psychedelic research, indigenous
evidence-based approach reciprocity: not that simple
hexaflex model and psychedelic therapy

BILL BRENNAN
BRIAN PACE Introducing EMBARK: a trans-diagnostic, KIRRAN AHMAD
14:40 - 15:00 Right-wing psychedelia: red pills for sale 14:40 - 15:00
trans-drug model of psychedelic-assisted Ibogaine & reciprocity
psychotherapy and therapist training

15:00
12:20- -15:10
12:50 ROOM CHANGE 15:00 - 15:10
 FRIDAY 23 SEPTEMBER

HUXLEY HALL SHULGIN STAGE WASSON ROOM

(Re)framing the psychedelic Ethics and professional conduct

Deleuze and psychedelics
renaissance in psychedelic therapy

DAAN VAN OOSTVEEN CAROLINA SEYBERT JOÃO GUILHERME RIBEIRO

15:10 - 15:30 Posthuman psychedelics: how to move Ethical challenges of altered states of Into the virtual: a Deleuzian account of 15:10 - 15:30
beyond health and capital consciousness in the treatment setting psychedelic experience

ROBERT SCHOEVERS JOS TEN BERGE

DAVID DUPUIS Modernist discourse, or how cultural 15:30 - 15:50
15:30 - 15:50 Psychedelic treatments and the risk of boundary
Can psychedelics really change the world? history influenced drug research
violations

15:50 - 16:20 BREAK 15:50 - 16:20

PANEL
SYMPOSIUM Therapeutic processes and
Psychedelic therapy: ethics, risks,
Belief changes and mysticism intentions
and professional boundaries

DAVID YADEN ROBERTA MURPHY

Agnostic frames for metaphysical claims The impact of the therapeutic alliance
in psychedelic experiences 16:20 - 16:40
on the acute psychedelic experience
SAMULI KANGASLAMPI
and clinical outcomes in depression
The role of mystical-type experiences in Panelists
improved well-being after psychedelic MONNICA WILLIAMS
use – a comprehensive review of the PETER GASSER JORDAN SLOSHOWER
evidence
CORINE DE BOER The role of psychological flexibility in
16:20 - 17:20 PETER SJÖSTEDT-HUGHES 16:40 - 17:00
On the need for metaphysics in
ASHLEIGH MURPHY-BEINER psilocybin-assisted therapy of major
psychedelic research
depression
JOSJAN ZIJLMANS Moderator
Moving past mysticism in psychedelic ROBERT SCHOEVERS
science MARIA AMATO
JUSSI JYLKKÄ A qualitative analysis of over 2000
17:00 - 17:20
Naturalism and mysticism in psychedelic participants' intentions to participate
science in a psychedelic retreat

17:20 - 17:30 ROOM CHANGE 17:20 - 17:30

PANEL PANEL
Mainstreaming psychedelics: The role of music in psychedelic therapy Funding and regulating medical
democratization and medicalization psychedelics in Europe

Panelists
Panelists
LIONEL THELEN
RICK DOBLIN
JULIA MANDE GITTE MOOS KNUDSEN
MENDEL KAELEN
MATTHIAS LIECHTI TADEUSZ HAWROT
17:30 - 18:15 The essential role of music in psychedelic 17:30 - 18:15
SHAYLA LOVE FLORENCE BUTLEN-DUCUING

therapy: 10 years of research

Moderator Moderator
THIJS ROES
DAVID NUTT

18:15 - 19:15 RELAX & CONNECT 18:15 - 19:15

 SATURDAY 24 SEPTEMBER
9:00 - 9:30 ARRIVAL 9:00 - 9:30

HUXLEY HALL SHULGIN STAGE WASSON ROOM

Critical perspectives on the

Mapping the psychedelic brain Methylone
quality of psychedelic research

CHRISTINE HAUSKELLER KATRIN PRELLER JENNIFER SCHMIDT

Methylone, a rapid acting entactogen with
9:30 - 9:55 Problems with clinical trials in The effects of psychedelics on the robust antidepressant-like activity in the
9:30 - 9:55
psychedelic-assisted therapies human brain forced swim test

MICHIEL VAN ELK GITTE MOOS KNUDSEN BEN KELMENDI

9:55 - 10:20 A roadmap for improving Sustained effects of single doses of A case series presenting clinical evidence for 9:55 - 10:20
psychedelic science classical psychedelics in humans the use of methylone in the treatment of PTSD

10:20 - 10:30 ROOM CHANGE 10:20 - 10:30

PANEL Psychedelic and psychiatric

Clinical trials vs. patient needs
Psychedelics: science meets business drug interactions

Panelists EDWARD JACOBS KELAN THOMAS

ULF BREMBERG When the trial ends: the ethical and pragmatic Integrating psychedelic therapy into psychiatry:
case for post-trial provisions in clinical 10:30 - 10:55
evaluating the potential risks of combining psychedelics
SHERRY RAIS
psychedelic research and psychiatric medications in clinical practice
10:30 - 11:20 AMIR INAMDAR
KIM KUYPERS
JAN THOMANN

LEONIE SCHNEIDER & IAN ROULLIER
Moderator Drug metabolism and pharmacokinetics 10:55 - 11:20
The importance of the participant voice of psilocin in vitro and in humans
SHAYLA LOVE

11:20 - 11:50 BREAK 11:20 - 11:50

MDMA-assisted therapy PANEL FILM SCREENING

around the world Participant perspectives on psychedelic trials Descending the Mountain

CORINE DE BOER
11:50 - 12:10 MDMA-assisted therapy clinical trials in
PTSD in Europe: an update Panelists
LEONIE SCHNEIDER
IAN ROULLIER
Followed by Q&A with co-producer
PEDRAM DARA 11:50 - 12:50
RICK DOBLIN ANNETTE BADENHORST

12:10 - 12:50 MDMA: from therapy drug to party

Moderator
drug back to therapy drug and beyond
JOOST BREEKSEMA

12:50 - 14:20 LUNCH & POSTER PRESENTATIONS 12:50 - 14:20

14:00 - 14:10 INTROSPECTIVE MUSIC JOURNEY

14:00 - 14:10

Psychedelics Insights & illusions in Indigenous medicine in/beyond

and the nature of reality psychedelic therapy the Amazon

(ONLINE) RUBEN LAUKKONEN ANDRÉ VAN DER BRAAK

A theory of true and false insight:
implications for psychedelic therapy
BERNARDO KASTRUP
14:20 - 15:00 Psychedelic effects are one piece
12:20 - 12:50 CHRISTOPHER TIMMERMANN
of a much bigger puzzle
Psychedelic apprenticeship in clinical
practice, traditional contexts, and
consciousness science
Making sense of ayahuasca religiosity in 14:20 - 14:40
the West: a Latourian approach
ILANA BERLOWITZ
Indigenous Amazonian therapy using liquid
14:40 - 15:00
psychoactive tobacco as medicine: results from a
multimodal transdisciplinary clinical study

15:00 - 15:10 ROOM CHANGE 15:00 - 15:10

 SATURDAY 24 SEPTEMBER

HUXLEY HALL SHULGIN STAGE WASSON ROOM

Psilocybin, consciousness Charting the way forward

Microdosing II
and mysticism in psychedelic research

ROTEM PETRANKER ALEKSI HUPLI

(ONLINE) ROLAND GRIFFITHS
Psilocybin-occasioned mystical-type
15:10 - 15:50 experiences: implications for
consciousness, altruism, and
spirituality
Manifest your desires: psychedelics
and the self-help industry
TEHSEEN NOORANI
Reimagining (psychedelic) drug
evaluation processes
Using digital tools to study emerging drug 15:10 - 15:30
trends: psychedelic microdosing on YouTube
MAGGIE KIGARA
Personal science to maximize scientific
15:30 - 15:50
impact: n-of-1 report of the world’s largest
mobile microdosing study

15:50 - 16:20 BREAK 15:50 - 16:20

PANEL
Lessons for psychedelic Literary, cultural, and
Blinding, expectancy and hype:
therapists linguistic perspectives
reimagining psychedelic trials

PATRICK EVERITT
‘Whenever in doubt, turn off your mind,
relax, float downstream’: The Psychedelic 16:20 - 16:40
PETER GASSER
Experience (1964) – an early manual of
16:20 - 16:50 Working as a couple in psychedelic

entheogenic esotericism
therapy. Dreams – Difficulties – Dangers.
Panelists
MICHIEL VAN ELK JOHANNA SOPANEN
ROTEM PETRANKER Journeying in the unconscious;
16:40 - 17:00
ERIKA DYCK Jung's Liber Novus and the

psychedelic experience

JANIS PHELPS Moderator

Radical commitment to self-reflection TEHSEEN NOORANI
16:50 - 17:20
and peer review: 10 values and skills of MARK SCHUNEMANN
the ethical psychedelic therapist Entities in lysergic literature - history 17:00 - 17:20
or mystery

17:20 - 17:30 ROOM CHANGE 17:20 - 17:30

17:30 - 18:15 CLOSING PANEL 17:30 - 18:15

18:15 - 19:15 RELAX & CONNECT 18:15 - 19:15